Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALDER: MC0518 vs BAT in Paediatric Steroid-refractory aGvHD
NCT06075706Phase 2Active, not recruiting
- Sponsor
- medac GmbH
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Stem Cell Therapies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of mesenchymal stromal cells, ex vivo cultured in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by medac GmbH. Primary endpoint: Overall Response at Day 28. Started Nov 2023; status: active, not recruiting.
02
Drugs
mesenchymal stromal cells, ex vivo cultured
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06075706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075706.